Stock Research for SNY

Featured Broker: Ally Invest

Get the due diligence for another stock.


SNY Stock Chart & Research Data

The SNY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SNY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


SNY Due diligence Resources & Stock Charts

The SNY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View SNY Detailed Price Forecast - CNN Money CNN View SNY Detailed Summary - Google Finance
Yahoo View SNY Detailed Summary - Yahoo! Finance Zacks View SNY Stock Research & Analysis -

Stock Analysis

TradeIdeas View SNY Trends & Analysis - Trade-Ideas Barrons View SNY Major Holders - Barrons
NASDAQ View SNY Call Transcripts - NASDAQ Seeking View SNY Breaking News & Analysis - Seeking Alpha
Spotlight View SNY Annual Report - OTC Report View SNY OTC Short Report -
TradeKing View SNY Fundamentals - TradeKing Charts View SNY SEC Filings - Bar Chart
WSJ View Historical Prices for SNY - The WSJ Morningstar View Performance/Total Return for SNY - Morningstar
MarketWatch View the Analyst Estimates for SNY - MarketWatch CNBC View the Earnings History for SNY - CNBC
StockMarketWatch View the SNY Earnings - StockMarketWatch MacroAxis View SNY Buy or Sell Recommendations - MacroAxis
Bullish View the SNY Bullish Patterns - American Bulls Short Pains View SNY Short Pain Metrics -

Social Media Mentions

StockTwits View SNY Stock Mentions - StockTwits PennyStocks View SNY Stock Mentions - PennyStockTweets
Twitter View SNY Stock Mentions - Twitter Invest Hub View SNY Investment Forum News - Investor Hub
Yahoo View SNY Stock Mentions - Yahoo! Message Board Seeking Alpha View SNY Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for SNY - Insider Cow View Insider Transactions for SNY - Insider Cow
CNBC View SNY Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for SNY - OTC Markets
Yahoo View Insider Transactions for SNY - Yahoo! Finance NASDAQ View Institutional Holdings for SNY - NASDAQ

Stock Charts

FinViz View SNY Stock Insight & Charts - StockCharts View SNY Investment Charts -
BarChart View SNY Stock Overview & Charts - BarChart Trading View View SNY User Generated Charts - Trading View

Latest Financial News for SNY

Why Dicerna Rocketed Higher Today
Posted on Friday April 20, 2018

Investors are happy the biotech ended a lawsuit hanging over its head.

WHO recommends testing before use of Sanofi's dengue vaccine
Posted on Thursday April 19, 2018

The World Health Organisation on Thursday said Sanofi's vaccine against dengue should only be used after testing individuals to assess whether they could have been exposed before to the infection. "We have now clear information that the vaccine needs to be dealt in a safer way by using it exclusively in people already infected," Alejandro Cravioto, Chair of the WHO's Strategic Advisory Group of Experts (SAGE) on Immunization, told journalists. After new analysis of data, Sanofi warned in November the vaccine could increase the risk of severe dengue in some cases in people who had not been previously exposed to the disease.

Sanofi to Divest European Generic Unit, Streamline Business
Posted on Thursday April 19, 2018

Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.

Analysts’ Recommendations for Novartis on April 17
Posted on Wednesday April 18, 2018

Novartis AG (NVS) reported revenue of $12.9 billion and EPS (earnings per share) of $1.21 in 4Q17, a 4.8% rise in revenue compared to 4Q16. For 1Q18, analysts expect Novartis to see EPS of $1.28 on revenue of $12.6 billion.

Enter a stock symbol to view the stock details.